4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. scores highest on Nitro (73) and lowest on Earnings (19). Its PosiPenta is 42.50 out of 100, around the middle of similar companies.
On the Penta Grid this week, 4D Molecular Therapeutics, Inc. is Grid #454 of 837 in the Healthcare sector in United States, and Grid #2,645 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. | 42.50 | 32 | 19 | 73 | 52 | 37 |
| Ginkgo Bioworks Holdings, Inc. | 39.65 | 32 | 33 | 60 | 30 | 43 |
| Design Therapeutics, Inc. | 46.57 | 21 | 29 | 63 | 65 | 54 |
| Wave Life Sciences, Inc. | 34.16 | 35 | 34 | 12 | 45 | 45 |
| Attovia Therapeutics, Inc. | 36.71 | 0 | 28 | 38 | 62 | 55 |
| Lexicon Pharmaceuticals, Inc. | 41.25 | 17 | 44 | 56 | 45 | 44 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -4.67 |
| P/B ratio | 1.65 |
EEarnings
| Trailing EPS | ₹-246.26 |
| Forward EPS | ₹-387.75 |
NNitro
| Price | 1149.84 |
| 52-week high | 1603.52 |
| 52-week low | 659.22 |
| Fall from 52-week high | 28.3% |
TTorque
| Return on equity (ROE) | -43.25% |
| Debt-to-equity | 0.10 |
AAnchor
| Beta (price swings) | 2.74 |
| Market cap | ₹6,352 Cr |
| Insider holding | 2.72% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is 4D Molecular Therapeutics, Inc.'s PosiPenta score?
4D Molecular Therapeutics, Inc.'s PosiPenta is 42.50 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does 4D Molecular Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, 4D Molecular Therapeutics, Inc. is Grid #454 of 837 in the Healthcare sector in United States, and Grid #2,645 of 4,000 in United States.
Which PosiPenta pillar is strongest for 4D Molecular Therapeutics, Inc.?
Nitro (momentum), with a score of 73 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for 4D Molecular Therapeutics, Inc.?
Earnings (growth), with a score of 19 out of 100: much weaker than most similar companies.
Has 4D Molecular Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 2.66 points, from 39.84 to 42.50.
PositoAI is for research and education only and is not investment advice.